Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Single-dose CAR-T therapy potentially curative in multiple myeloma by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

Existing risk stratification models for multiple myeloma characterize patients as "high" or "low" risk based on measures of tumor burden. These models do not include genetic factors.

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...

Multiple myeloma is most common in people age 65 and older. The average age of diagnosis is 70, with fewer than 1% of cases diagnosed in people younger than 35.